Okan Kuzhan | Acibadem University (original) (raw)

Papers by Okan Kuzhan

Journal of Clinical Oncology, May 20, 2010

e19507 Background: Ibandronate is a third generation bisphosphonate with analgesic effects demons... more e19507 Background: Ibandronate is a third generation bisphosphonate with analgesic effects demonstrated in previous phase III trials. Renal safety of ibandronate enables using higher-dose regimens....

Turkiye Klinikleri Radiation Oncology - Special Topics, 2019

Journal of Clinical Oncology, Jun 20, 2006

16517 Background: Optimal therapeutic modality and duration of adult Burkitt and lymphoblastic ly... more 16517 Background: Optimal therapeutic modality and duration of adult Burkitt and lymphoblastic lymphoma (LL) are still unknown. Despite long-lasting and intensive chemotherapy administration, post-therapy relapses are common. METHODS In this single center phase-II prospective study, high-dose therapy (HDC) and autologous peripheral blood stem cell transplantation (APSCT) was done during the first remission following induction and consolidation therapy for 18 patients with Burkitt (n: 5) and LL (n: 13) without bone marrow and central nervous system involvement at presentation. Cyclophosphamide, vincristine, prednisolone, adriamycin with or without L-asparaginase induction regimen was followed by dexamethasone, cytarabine, and cisplatin consolidation therapy with total body irradiation and cyclophoshamide conditioning. RESULTS Mean patient age was 24.6 (range: 21-55) years and male to female ratio was 5 to1. 44% (8/18) of the patients were in the intermediate and high-risk groups of International Prognostic Index. Median treatment duration until APSCT was 104 days (range: 87-128). 83% and 17% of the patients were in complete and partial remission before transplantation. One patient with Burkitt lymphoma out of 5 (20%) and 6 patients with LL out of 13 (46%) have died of progression. Overall survival (OS) at 113-month follow-up for all patients was 59.03% with 59.26% of disease-free survival (DFS). However, LL cases revealed OS and DFS rates of 50.35% and 50.77%, respectively. Only one early death (5.5%) was noted due to liver toxicity following HDC and APSCT. CONCLUSIONS In conclusion, this single center phase-II study reveals an acceptable toxicity, short treatment period and high survival rate in adult Burkitt and LL cases, suggesting APSCT to be a good treatment option in the first remission. No significant financial relationships to disclose.

Journal of Clinical Oncology, May 20, 2009

7099 Background: 10 microg/kg/day of filgrastim and lenograstim have been recommended for mobiliz... more 7099 Background: 10 microg/kg/day of filgrastim and lenograstim have been recommended for mobilization of CD34+ cells without associated chemotherapy. However,in our previous randomized study we demonstrated that a 7.5 microg/kg/day dose of lenograstim has been as efficacious as 10 microg/kg/day of filgrastim. In this study, we investigated whether a reduced dose of lenograstim is equavalent to standard dose for autologous peripheral blood stem cell (PBSC) mobilization and transplantation. Methods: A total of 49 consecutive patients were randomized to either low dose (7.5 microg/kg/day, n = 24) or standard dose (10 microg/kg/day, n = 25) of lenograstim. These two groups were similar in regard to disease, sex, body weight, body surface area, conditioning regimens, previous chemotherapy cycles and radiotherapy. Each dose of lenograstim was administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In the posttransplant period, lenograstim was given at 5 microg/kg/day until leukocyte engraftment. Results: Successful mobilization with the first apheresis, was achieved in 10/24 (42%) patients in low dose group versus 14/25 (56%) patients in standard dose group. No significant difference was seen in the median number of CD34+cells mobilized, as well as the median number of apheresis, median volume of apheresis, percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions were similar in both groups in the posttransplant period. Conclusions: Lenograstim 7.5 microg/kg/day is as efficious as Lenograstim 10 microg/kg/day for autologous PBSC mobilization and transplantation. No significant financial relationships to disclose.

PubMed, Jun 1, 2005

Primary cutaneous B-cell lymphomas (PCBCL) are rare and constitute 5-10% of all cutaneous lymphom... more Primary cutaneous B-cell lymphomas (PCBCL) are rare and constitute 5-10% of all cutaneous lymphomas. In patients with PCBCL presenting with solitary or localized skin lesions, radiotherapy is the preferred treatment. Two patients who were treated with 4 MeV electrons, both obtained remission for 51 months. Unfortunately, at the last visit one patient relapsed on the border of the radiotherapy field and was re-treated with a generous irradiation field in 2004. Complete response was obtained again. Thus, for localized PCBCL, radiotherapy alone is an effective treatment.

Journal of Clinical Oncology, May 20, 2013

quizartinib with standard induction in patients with acute myeloid leukaemia and FLT3 mutations a... more quizartinib with standard induction in patients with acute myeloid leukaemia and FLT3 mutations are ongoing (NCT02039726, NCT02668653). Sorafenib is a multikinase inhibitor with FLT3 inhibitory activity. Encouraging results have been reported in patients with acute myeloid leukaemia and FLT3 mutations in combination with either intensive chemotherapy or with hypomethylating therapy. 9 Crenolanib is a type I FLT3 inhibitor developed to target internal tandem duplications and mutations in codon D835 of FLT3 that has shown clinical activity in patients with relapsed acute myeloid leukaemia. 10 In conclusion, the data for gilteritinib as a single agent are encouraging, and the results of combination regimens with this agent are awaited eagerly. Several other FLT3 inhibitors are in advanced clinical development and will hopefully improve the outcomes for patients with acute myeloid leukaemia and with (and possibly without) mutations in FLT3.

Tumori Journal, 2006

Aim To evaluate the efficacy of postoperative irradiation in renal cell carcinoma. Patients and m... more Aim To evaluate the efficacy of postoperative irradiation in renal cell carcinoma. Patients and methods Forty patients with localized renal cell carcinoma admitted to our hospital between 1986 and 1999 were evaluated. All patients were initially treated with radical nephrectomy. Postoperative radiotherapy was given to 26 of 40 patients (65%). Fourteen patients (35%) received no adjuvant therapy. Median age was 55 years (range, 20–70 years). Twenty-four patients (60%) were men and 16 patients (40%) were women. Histopathological diagnosis was renal cell carcinoma in all of the patients. N+ disease was present in 3 patients (7%). Stage I and II disease was present in 25 patients (63%) and stage III and IV disease in 15 patients (37%). Two patients (5%) had T1a disease, 11 patients (27%) had T1b, 15 patients (38%) had T2, 11 patients (27%) had T3a and 1 (3%) patient had T3b. In the radiotherapy group, renal bed and regional lymphatic fields were irradiated with daily fractions of 180–20...

GÜLHANE TIP …, 2004

... Dr. Selim KILIÇ (*), Dr. Şeref KÖMÜRCÜ (**), Dr. Maharet RZAYEV (*), Dr. Ahmet ÖZET (**), Dr.... more ... Dr. Selim KILIÇ (*), Dr. Şeref KÖMÜRCÜ (**), Dr. Maharet RZAYEV (*), Dr. Ahmet ÖZET (**), Dr. Tayfun KIR (*), Dr. Fikret ARPACI (**), Dr. Cengiz Han AÇIKEL (*), Dr. Bekir ÖZTÜRK (**), Dr. Recai OĞUR (*) Dr. Selmin ATAERGİN (**), Dr. Okan KUZHAN (**), Dr. Metin HASDE (*) ...

... Dr. Sabahat TEZCAN (**), Dr. Şeref KÖMÜRCÜ (***) Dr. Ahmet ÖZET (***) Dr. Banu ÇAKIR (**), Dr... more ... Dr. Sabahat TEZCAN (**), Dr. Şeref KÖMÜRCÜ (***) Dr. Ahmet ÖZET (***) Dr. Banu ÇAKIR (**), Dr. Nazmi TÜMERDEM (*), Dr. Bilal BAKIR (*), Dr ... 1. İrgil, E.: Meme Kanseri Epidemiyolojisi, Meme Hastalıkları, Editörler: Ünal G., Ünal H., 227-232, Nobel Tıp Kitabevleri, 2001. ...

Gülhane tıp dergisi, 1999

Gülhane tıp dergisi, 2012

Türk Hematoloji Onkoloji Dergisi, 1999

Journal of Clinical Oncology, 2006

18595 Background: In this study, we described four new cases of bisphosphonates-related jaw osteo... more 18595 Background: In this study, we described four new cases of bisphosphonates-related jaw osteonecrosis and reviewed the English Medical Literature for similar case reports. Methods: A MEDLINE literature search was performed from September 2003 to November 2005 for all case reports of bisphosphonates-associated jaw osteonecrosis. Results: Our patients were three female and one male with a median age of 50.5 years (range, 35–57 years). Two patients had breast cancer and two another had multiple myeloma. Two patients received pamidronate initially and were switched later to zoledronate. The two other patients were treated with zoledronate. The median duration from the first administration of bisphosphonates to the diagnosis of osteonecrosis was 48 (range, 18–75) months. Review of the literature of all published cases revealed 184 patients. Age of these patients ranged from 37 to 89 years (median, 64 years). Seventy-eight patients (43.4%) were treated with bisphosphonates for metasta...

Journal of Oncology Pharmacy Practice, 2019

IntroductionInflammatory myofibroblastic tumor is a rare disease which is typically seen in child... more IntroductionInflammatory myofibroblastic tumor is a rare disease which is typically seen in children and young adults. Approximately half of the inflammatory myofibroblastic tumors contain translocations that result in over-expression of anaplastic lymphoma kinase gene. Herein, we present two anaplastic lymphoma kinase-positive cases with long-term remission with crizotinib. We do not know how long these therapies need to be continued.Case reportsWe present two cases of inflammatory myofibroblastic tumor treated with anaplastic lymphoma kinase inhibitor therapies: an 8-year-old Turkish boy and a 21-year-old Caucasian man.Management and outcomeTwo cases, both with good tumor control under crizotinib, but one who progressed on drug holiday, responded again to the same drug, and had a very short period of response after restarting crizotinib.ConclusionA molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammato...

Tumori Journal, 2006

Aims and Background To report our experience of patients with primary glioblastoma multiforme of ... more Aims and Background To report our experience of patients with primary glioblastoma multiforme of young age by evaluating the characteristics, prognostic factors, and treatment outcomes. Patients and Methods Seventy patients with primary glioblastoma multiforme (GBM) treated at our department between 1996 and 2004 were studied. The male-female ratio was 2.6:1. The median age was 53 (16-74). Sixty-eight patients (97%) were operated on before radiotherapy and 2 patients (3%) underwent only stereotactic biopsy. All patients received radiotherapy. Postoperative chemotherapy as an adjuvant to radiotherapy was given to 9 patients (12%). The patients were divided into 2 groups according to their age (group A ≤35 years, n = 21 vs group B >35 years, n = 49). Survival was determined with the Kaplan-Meier method and differences were compared using the log-rank test. Cox regression analysis was performed to identify the independent prognostic factors. Karnofsky performance status (≥70 vs <...

Journal of Clinical Oncology, 2008

12028 Background: No combination chemotherapy has been shown yet to be more effective in metastat... more 12028 Background: No combination chemotherapy has been shown yet to be more effective in metastatic breast cancer patients who did not either respond to taxanes and anthracyclines or recurred thereafter. Methods: Between January and September 2007, totally 11 patients were enrolled. All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. They were given oral capecitabin (2X 1,000 mg/m2) and oral cychlophosphamide (3X 30 mg/m2) on days 1 to 14 every 3 weeks. The chemotherapy continued until progression. Response to treatment was evaluated with imaging studies every two months. Duration of response was calculated by counting the months elapsed from the established response to progression or to date of last visit. Results: Median age of patients was 48 (33–60) years. At presentation, one patient had metastatic disease, 4 (36.4%) had stage III disease, and 6 (54.5%) had stage II disease. Five (45.5%) had ER positive, 4 (36.4%) had PR positive, and 7 (63.6%) had...

Turkiye Klinikleri Journal of Surgical Medical Sciences, 2006

Turkish Journal of Cancer, Jul 1, 2008

World Journal of Medical Sciences

2 Abstract: Rhabdomyosarcoma (RMS) is an uncommon neoplasm in adult population. Outcome for adult... more 2 Abstract: Rhabdomyosarcoma (RMS) is an uncommon neoplasm in adult population. Outcome for adult RMS is poorly documented due to its rarity. Published series have reported worse results for adults compared with children with RMS. Eighteen adult patients with RMS whose age were 17 years and older were treated between 1979 and 2004 and were analyzed retrospectively for treatment outcome. Univariate statistical methods were used to evaluate outcome. Patient ages ranged from 17 to 70 (median 21). Embryonal RMS was the most common subtype. Anatomic sites of origin were extremity (33.3%), genitourinary tract (33.3%), head and neck (22.2%) and trunk (11.2%). Tumor size was 5 cm or smaller in 39% of patients. Regional lymph node metastasis was present in 17% of patients at presentation. Treatment consisted of radiation therapy (RT) alone in 6%, RT and surgery in 11%, RT and chemotherapy in 44% and all three modalities in 39%. With a median follow-up of 61 months, the 4-year overall surviva...

Medical Principles and Practice, 2009

Objective: To report an unusual paraneoplastic syndrome, amyotrophic lateral sclerosis, associate... more Objective: To report an unusual paraneoplastic syndrome, amyotrophic lateral sclerosis, associated with renal cell carcinoma. Case Presentation and Intervention: A 59-year-old man presented with muscle weakness and fasciculations in the upper extremities. Neurological examination showed that the fasciculations arose spontaneously in the upper limbs. Electrodiagnostic studies revealed an active neurogenic disorder. The patient was diagnosed with a motor neuron disease mimicking amyotrophic lateral sclerosis. Urine analysis revealed microscopic hematuria. Abdominal computerized tomography scans showed a 9.5 × 8 cm renal mass in the lower pole of the right kidney. Curative right radical nephrectomy was performed. Pathologic examination showed a clear cell adenocarcinoma. After nephrectomy, the muscle weakness and fasciculations disappeared spontaneously within 2 months. The patient was disease-free for 58 months after right radical nephrectomy. He complained of muscle weakness and fasc...

Journal of Clinical Oncology, May 20, 2010

e19507 Background: Ibandronate is a third generation bisphosphonate with analgesic effects demons... more e19507 Background: Ibandronate is a third generation bisphosphonate with analgesic effects demonstrated in previous phase III trials. Renal safety of ibandronate enables using higher-dose regimens....

Turkiye Klinikleri Radiation Oncology - Special Topics, 2019

Journal of Clinical Oncology, Jun 20, 2006

16517 Background: Optimal therapeutic modality and duration of adult Burkitt and lymphoblastic ly... more 16517 Background: Optimal therapeutic modality and duration of adult Burkitt and lymphoblastic lymphoma (LL) are still unknown. Despite long-lasting and intensive chemotherapy administration, post-therapy relapses are common. METHODS In this single center phase-II prospective study, high-dose therapy (HDC) and autologous peripheral blood stem cell transplantation (APSCT) was done during the first remission following induction and consolidation therapy for 18 patients with Burkitt (n: 5) and LL (n: 13) without bone marrow and central nervous system involvement at presentation. Cyclophosphamide, vincristine, prednisolone, adriamycin with or without L-asparaginase induction regimen was followed by dexamethasone, cytarabine, and cisplatin consolidation therapy with total body irradiation and cyclophoshamide conditioning. RESULTS Mean patient age was 24.6 (range: 21-55) years and male to female ratio was 5 to1. 44% (8/18) of the patients were in the intermediate and high-risk groups of International Prognostic Index. Median treatment duration until APSCT was 104 days (range: 87-128). 83% and 17% of the patients were in complete and partial remission before transplantation. One patient with Burkitt lymphoma out of 5 (20%) and 6 patients with LL out of 13 (46%) have died of progression. Overall survival (OS) at 113-month follow-up for all patients was 59.03% with 59.26% of disease-free survival (DFS). However, LL cases revealed OS and DFS rates of 50.35% and 50.77%, respectively. Only one early death (5.5%) was noted due to liver toxicity following HDC and APSCT. CONCLUSIONS In conclusion, this single center phase-II study reveals an acceptable toxicity, short treatment period and high survival rate in adult Burkitt and LL cases, suggesting APSCT to be a good treatment option in the first remission. No significant financial relationships to disclose.

Journal of Clinical Oncology, May 20, 2009

7099 Background: 10 microg/kg/day of filgrastim and lenograstim have been recommended for mobiliz... more 7099 Background: 10 microg/kg/day of filgrastim and lenograstim have been recommended for mobilization of CD34+ cells without associated chemotherapy. However,in our previous randomized study we demonstrated that a 7.5 microg/kg/day dose of lenograstim has been as efficacious as 10 microg/kg/day of filgrastim. In this study, we investigated whether a reduced dose of lenograstim is equavalent to standard dose for autologous peripheral blood stem cell (PBSC) mobilization and transplantation. Methods: A total of 49 consecutive patients were randomized to either low dose (7.5 microg/kg/day, n = 24) or standard dose (10 microg/kg/day, n = 25) of lenograstim. These two groups were similar in regard to disease, sex, body weight, body surface area, conditioning regimens, previous chemotherapy cycles and radiotherapy. Each dose of lenograstim was administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In the posttransplant period, lenograstim was given at 5 microg/kg/day until leukocyte engraftment. Results: Successful mobilization with the first apheresis, was achieved in 10/24 (42%) patients in low dose group versus 14/25 (56%) patients in standard dose group. No significant difference was seen in the median number of CD34+cells mobilized, as well as the median number of apheresis, median volume of apheresis, percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions were similar in both groups in the posttransplant period. Conclusions: Lenograstim 7.5 microg/kg/day is as efficious as Lenograstim 10 microg/kg/day for autologous PBSC mobilization and transplantation. No significant financial relationships to disclose.

PubMed, Jun 1, 2005

Primary cutaneous B-cell lymphomas (PCBCL) are rare and constitute 5-10% of all cutaneous lymphom... more Primary cutaneous B-cell lymphomas (PCBCL) are rare and constitute 5-10% of all cutaneous lymphomas. In patients with PCBCL presenting with solitary or localized skin lesions, radiotherapy is the preferred treatment. Two patients who were treated with 4 MeV electrons, both obtained remission for 51 months. Unfortunately, at the last visit one patient relapsed on the border of the radiotherapy field and was re-treated with a generous irradiation field in 2004. Complete response was obtained again. Thus, for localized PCBCL, radiotherapy alone is an effective treatment.

Journal of Clinical Oncology, May 20, 2013

quizartinib with standard induction in patients with acute myeloid leukaemia and FLT3 mutations a... more quizartinib with standard induction in patients with acute myeloid leukaemia and FLT3 mutations are ongoing (NCT02039726, NCT02668653). Sorafenib is a multikinase inhibitor with FLT3 inhibitory activity. Encouraging results have been reported in patients with acute myeloid leukaemia and FLT3 mutations in combination with either intensive chemotherapy or with hypomethylating therapy. 9 Crenolanib is a type I FLT3 inhibitor developed to target internal tandem duplications and mutations in codon D835 of FLT3 that has shown clinical activity in patients with relapsed acute myeloid leukaemia. 10 In conclusion, the data for gilteritinib as a single agent are encouraging, and the results of combination regimens with this agent are awaited eagerly. Several other FLT3 inhibitors are in advanced clinical development and will hopefully improve the outcomes for patients with acute myeloid leukaemia and with (and possibly without) mutations in FLT3.

Tumori Journal, 2006

Aim To evaluate the efficacy of postoperative irradiation in renal cell carcinoma. Patients and m... more Aim To evaluate the efficacy of postoperative irradiation in renal cell carcinoma. Patients and methods Forty patients with localized renal cell carcinoma admitted to our hospital between 1986 and 1999 were evaluated. All patients were initially treated with radical nephrectomy. Postoperative radiotherapy was given to 26 of 40 patients (65%). Fourteen patients (35%) received no adjuvant therapy. Median age was 55 years (range, 20–70 years). Twenty-four patients (60%) were men and 16 patients (40%) were women. Histopathological diagnosis was renal cell carcinoma in all of the patients. N+ disease was present in 3 patients (7%). Stage I and II disease was present in 25 patients (63%) and stage III and IV disease in 15 patients (37%). Two patients (5%) had T1a disease, 11 patients (27%) had T1b, 15 patients (38%) had T2, 11 patients (27%) had T3a and 1 (3%) patient had T3b. In the radiotherapy group, renal bed and regional lymphatic fields were irradiated with daily fractions of 180–20...

GÜLHANE TIP …, 2004

... Dr. Selim KILIÇ (*), Dr. Şeref KÖMÜRCÜ (**), Dr. Maharet RZAYEV (*), Dr. Ahmet ÖZET (**), Dr.... more ... Dr. Selim KILIÇ (*), Dr. Şeref KÖMÜRCÜ (**), Dr. Maharet RZAYEV (*), Dr. Ahmet ÖZET (**), Dr. Tayfun KIR (*), Dr. Fikret ARPACI (**), Dr. Cengiz Han AÇIKEL (*), Dr. Bekir ÖZTÜRK (**), Dr. Recai OĞUR (*) Dr. Selmin ATAERGİN (**), Dr. Okan KUZHAN (**), Dr. Metin HASDE (*) ...

... Dr. Sabahat TEZCAN (**), Dr. Şeref KÖMÜRCÜ (***) Dr. Ahmet ÖZET (***) Dr. Banu ÇAKIR (**), Dr... more ... Dr. Sabahat TEZCAN (**), Dr. Şeref KÖMÜRCÜ (***) Dr. Ahmet ÖZET (***) Dr. Banu ÇAKIR (**), Dr. Nazmi TÜMERDEM (*), Dr. Bilal BAKIR (*), Dr ... 1. İrgil, E.: Meme Kanseri Epidemiyolojisi, Meme Hastalıkları, Editörler: Ünal G., Ünal H., 227-232, Nobel Tıp Kitabevleri, 2001. ...

Gülhane tıp dergisi, 1999

Gülhane tıp dergisi, 2012

Türk Hematoloji Onkoloji Dergisi, 1999

Journal of Clinical Oncology, 2006

18595 Background: In this study, we described four new cases of bisphosphonates-related jaw osteo... more 18595 Background: In this study, we described four new cases of bisphosphonates-related jaw osteonecrosis and reviewed the English Medical Literature for similar case reports. Methods: A MEDLINE literature search was performed from September 2003 to November 2005 for all case reports of bisphosphonates-associated jaw osteonecrosis. Results: Our patients were three female and one male with a median age of 50.5 years (range, 35–57 years). Two patients had breast cancer and two another had multiple myeloma. Two patients received pamidronate initially and were switched later to zoledronate. The two other patients were treated with zoledronate. The median duration from the first administration of bisphosphonates to the diagnosis of osteonecrosis was 48 (range, 18–75) months. Review of the literature of all published cases revealed 184 patients. Age of these patients ranged from 37 to 89 years (median, 64 years). Seventy-eight patients (43.4%) were treated with bisphosphonates for metasta...

Journal of Oncology Pharmacy Practice, 2019

IntroductionInflammatory myofibroblastic tumor is a rare disease which is typically seen in child... more IntroductionInflammatory myofibroblastic tumor is a rare disease which is typically seen in children and young adults. Approximately half of the inflammatory myofibroblastic tumors contain translocations that result in over-expression of anaplastic lymphoma kinase gene. Herein, we present two anaplastic lymphoma kinase-positive cases with long-term remission with crizotinib. We do not know how long these therapies need to be continued.Case reportsWe present two cases of inflammatory myofibroblastic tumor treated with anaplastic lymphoma kinase inhibitor therapies: an 8-year-old Turkish boy and a 21-year-old Caucasian man.Management and outcomeTwo cases, both with good tumor control under crizotinib, but one who progressed on drug holiday, responded again to the same drug, and had a very short period of response after restarting crizotinib.ConclusionA molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammato...

Tumori Journal, 2006

Aims and Background To report our experience of patients with primary glioblastoma multiforme of ... more Aims and Background To report our experience of patients with primary glioblastoma multiforme of young age by evaluating the characteristics, prognostic factors, and treatment outcomes. Patients and Methods Seventy patients with primary glioblastoma multiforme (GBM) treated at our department between 1996 and 2004 were studied. The male-female ratio was 2.6:1. The median age was 53 (16-74). Sixty-eight patients (97%) were operated on before radiotherapy and 2 patients (3%) underwent only stereotactic biopsy. All patients received radiotherapy. Postoperative chemotherapy as an adjuvant to radiotherapy was given to 9 patients (12%). The patients were divided into 2 groups according to their age (group A ≤35 years, n = 21 vs group B >35 years, n = 49). Survival was determined with the Kaplan-Meier method and differences were compared using the log-rank test. Cox regression analysis was performed to identify the independent prognostic factors. Karnofsky performance status (≥70 vs <...

Journal of Clinical Oncology, 2008

12028 Background: No combination chemotherapy has been shown yet to be more effective in metastat... more 12028 Background: No combination chemotherapy has been shown yet to be more effective in metastatic breast cancer patients who did not either respond to taxanes and anthracyclines or recurred thereafter. Methods: Between January and September 2007, totally 11 patients were enrolled. All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. They were given oral capecitabin (2X 1,000 mg/m2) and oral cychlophosphamide (3X 30 mg/m2) on days 1 to 14 every 3 weeks. The chemotherapy continued until progression. Response to treatment was evaluated with imaging studies every two months. Duration of response was calculated by counting the months elapsed from the established response to progression or to date of last visit. Results: Median age of patients was 48 (33–60) years. At presentation, one patient had metastatic disease, 4 (36.4%) had stage III disease, and 6 (54.5%) had stage II disease. Five (45.5%) had ER positive, 4 (36.4%) had PR positive, and 7 (63.6%) had...

Turkiye Klinikleri Journal of Surgical Medical Sciences, 2006

Turkish Journal of Cancer, Jul 1, 2008

World Journal of Medical Sciences

2 Abstract: Rhabdomyosarcoma (RMS) is an uncommon neoplasm in adult population. Outcome for adult... more 2 Abstract: Rhabdomyosarcoma (RMS) is an uncommon neoplasm in adult population. Outcome for adult RMS is poorly documented due to its rarity. Published series have reported worse results for adults compared with children with RMS. Eighteen adult patients with RMS whose age were 17 years and older were treated between 1979 and 2004 and were analyzed retrospectively for treatment outcome. Univariate statistical methods were used to evaluate outcome. Patient ages ranged from 17 to 70 (median 21). Embryonal RMS was the most common subtype. Anatomic sites of origin were extremity (33.3%), genitourinary tract (33.3%), head and neck (22.2%) and trunk (11.2%). Tumor size was 5 cm or smaller in 39% of patients. Regional lymph node metastasis was present in 17% of patients at presentation. Treatment consisted of radiation therapy (RT) alone in 6%, RT and surgery in 11%, RT and chemotherapy in 44% and all three modalities in 39%. With a median follow-up of 61 months, the 4-year overall surviva...

Medical Principles and Practice, 2009

Objective: To report an unusual paraneoplastic syndrome, amyotrophic lateral sclerosis, associate... more Objective: To report an unusual paraneoplastic syndrome, amyotrophic lateral sclerosis, associated with renal cell carcinoma. Case Presentation and Intervention: A 59-year-old man presented with muscle weakness and fasciculations in the upper extremities. Neurological examination showed that the fasciculations arose spontaneously in the upper limbs. Electrodiagnostic studies revealed an active neurogenic disorder. The patient was diagnosed with a motor neuron disease mimicking amyotrophic lateral sclerosis. Urine analysis revealed microscopic hematuria. Abdominal computerized tomography scans showed a 9.5 × 8 cm renal mass in the lower pole of the right kidney. Curative right radical nephrectomy was performed. Pathologic examination showed a clear cell adenocarcinoma. After nephrectomy, the muscle weakness and fasciculations disappeared spontaneously within 2 months. The patient was disease-free for 58 months after right radical nephrectomy. He complained of muscle weakness and fasc...